London11Charnwood Molecular is sponsoring a forthcoming scientific conference which promises to highlight the success of successful outsourcing to the biotechnology/pharmaceutical industry.

The outsourcing sector increasingly supports the pharmaceutical industry and the relationship between the two has developed enormously over the last 20 years – a development which Charnwood has embraced and built upon. With a sharp rise in outsourcing providers in the drug discovery sector, Charnwood has developed business in the area and continues to do so.

The event takes place on the 30th September 2014 at the Society of Chemical Industry in London, United Kingdom. The conference seeks to illustrate these developments along with current challenges and best practice as seen from the suppliers view point.

Speakers include those working in CROs from drug discovery through to development and will highlight what makes a successful collaboration, together with some potential pitfalls.

More details on the event are available here:

The Secrets of Success: CRO views of successful outsourcing

European Life Science Awards photo - CharnwoodCharnwood Molecular has been recognised for its unique collaborative venture with French company, Hybrigenics.

Working in conjunction with Hybrigenics Services, Charnwood’s expertise in chemical research contributed to the development of a yeast-chemical hybrid screening system, known as ULTImate YChemH. The system has now received the “Most Innovative New Service” of the year award, by the European Life Science Awards, presented to Hybrigenics Services, during the 4th Annual European Lab Automation Exhibition in Barcelona.

Charnwood Molecular’s involvement in the partnership sees the company using its expertise to link bio-active molecules for further analysis by Paris-based Hybrigenics Services,, using their yeast molecular biology machinery. The venture was the result of a two year long commercial trialling phase, which was supported by European funding.

The project is the result of a joint development venture amounting to a total investment of nearly one million Euros, which has been supported up to 40% of the costs by a European Union subsidy under the Eurostars® programme.

Using a chemical linkage adaptation of its optimized “Yeast Two-Hybrid” technology, renamed “yeast chemical-hybrid” (ULTImate YChemH), Hybrigenics Services screens the molecule provided by Charnwood Molecular as a “bait” against its cDNA or genomic libraries expressing millions of “prey” protein fragments to identify target proteins with which this tested molecule interacts.
These exhaustive screenings can be of interest from both safety and efficiency angles. It is hoped that the technology may uncover a full range of related targets, accounting for the whole spectrum of therapeutic activities of a drug (so-called “on-targets”) and/or explain unexpected side effects exerted through unsuspected targets (so-called “off-targets”). Some drugs are active in whole cellular or animal models, but their active mechanisms remain unknown: the ULTImate YChemH technology may find a relevant target for these “orphan” drugs, in a process called “drug de-orphanisation” It may also be relevant for widely used chemicals in every day products to ascertain that they do not interact with any protein.

“This Life Science Award is a great recognition of the breakthrough that the yeast-chemical hybrid system represents,” stated Dr Sylvain Blanc, Business Development Manager of Charnwood Molecular. “Now, just one year after launch, we are working hard to transform this technical achievement into a commercial success for both ourselves and Hybrigenics Services,” he added.

Charnwood involved in collaborative approach to new business

Charnwood Molecular has been featured in the RSC’s Chemistry World publication, for its innovative approach in new business development through collaborative working.

The full Chemistry World article is viewable here:
“Co-operation keeps contracts coming”

Charnwood works with other leading companies who are based at BioCity and actively encourages co-operation between companies in the facility.

This enables Charnwood to offer an “in-house” seamless, integrated discovery and development service by using the available resources within one facility and use the expertise of several other companies to provide this “single service solution”.

The grouping consists of separate entities with unparalleled expertise in a range of drug discovery fields, providing a fully integrated drug discovery capability.

CHARNWOOD MOLECULAR, a leading provider of chemistry services to the biotechnology, fine chemical and pharmaceutical industries, has invested in an additional research facility within BioCity Nottingham, UK.

With Charnwood Molecular’s reputation for excellence in synthesis and customer service, the expansion sees a move towards increased client focus.

Medicinal chemists at the company are experts in a wide range of therapeutic areas, including oncology, obesity,
immunology, respiratory disease, inflammation and the treatment of cardiovascular diseases.

The opening of the BioCity laboratory provides state of the art research space to support the company in its next stage of development, as demand for its contract research and custom synthesis services continues to grow from clients across the UK, Europe and the US.

The research facility compliments Charnwood’s original research site, which houses a twenty-strong research team and is located in Loughborough.

Dr. Paul Bradley, Head of Medicinal Chemistry at Charnwood Molecular states: “Our success in providing extremely high quality, yet cost-effective, solutions for contract research has led to an increasing demand for our services. BioCity Nottingham provides the perfect environment for an expanding business of this type, and we are particularly pleased to be able to contribute to the creation of new jobs in the East Midlands region, in a hightech sector.”

The expansion comes in line with Charnwood Molecular’s constant investment programme, which sees additional provision of synthetic services by investing in new equipment for synthesis, purification and analysis.

The new BioCity research facility compliments this approach and will allow significant opportunities for the company to undertake projects tailored to the specific requirements of the client, delivered by experienced postdoctoral chemists, working in state-of-the-art laboratory environments.

Charnwood Molecular prides itself on its client-focused approach, using the highest quality researchers and undertaking bespoke research specifically to clients’ needs, or providing clients with research chemicals.

The company’s track record for quality and delivery is a key driver and projects are completed on time, within budget and with the superior quality adherence that Charnwood’s clients have come to expect. The company is small enough to be responsive, to provide great flexibility in delivery and able to tackle more difficult, business critical, research projects.

CHARNWOOD MOLECULAR, a leading provider of chemistry services to the biotechnology, fine chemical and pharmaceutical industries, is looking to Switzerland to cement its international client base.

Charnwood, which has laboratories in Loughborough and BioCity, Nottingham, will be exploring opportunities with major players during meetings with a range of representatives, from big pharmaceutical companies to small biotech companies, in both Geneva and Basel, at the end of this month.

Charnwood has capitalised on the recent move by pharmaceutical companies to outsource some of their research activities, to reduce costs and the time it takes to identify a new drug and bring it to market.

As well as Swiss companies, Charnwood Molecular representatives will also meet with interested parties from nearby areas in France and Germany.

“At Charnwood, we already have clients across the globe, but Switzerland plays host to a range of key players in the pharmaceutical sector”, states Dr. Paul Bradley, Head of Medicinal Chemistry at Charnwood Molecular.  “We provide a range of services that are applicable to these companies, and our high quality, yet cost-effective, solutions for contract research has led to an increasing demand for our services.  The forthcoming trip will provide the perfect opportunity for us to let the Swiss representatives know of the expertise available at Charnwood and hopefully bring in more business.”

With Charnwood Molecular’s reputation for excellence in synthesis and customer service, the Swiss company representatives will be given a flavour of the company’s client focus.  This focus sees Charnwood use the highest quality researchers and undertake bespoke research specifically to clients’ needs, or providing clients with research chemicals on demand.

The visit is taking place as part of a trade mission, headed by Government export body UK Trade & Investment (UKTI).

CHARNWOOD MOLECULAR, a leading provider of chemistry services to the biotechnology, fine chemical and pharmaceutical industries, has partnered with French company, Hybrigenics, to launch a new service which identifies interactions between small molecules and protein targets.

Charnwood Molecular’s involvement in the partnership sees the company using its expertise to link molecules for further analysis by Paris-based Hybrigenics, using their yeast molecular biology machinery.  The venture is the result of a two year long commercial trialling phase, which was supported by European funding.

The project is the result of a joint development venture amounting to a total investment of nearly one million Euros, which has been supported up to 40% of the costs by a European Union subsidy under the Eurostars® programme.

Using a chemical linkage adaptation of its optimized “yeast two-hybrid” technology, renamed “yeast chemical-hybrid” (YChemH), Hybrigenics Services screens the molecule provided by Charnwood Molecular as a “bait” against its cDNA or genomic libraries expressing millions of “prey” protein fragments to identify target proteins with which this tested molecule interacts.

These exhaustive screenings can be of interest from both safety and efficiency angles. It is hoped that the technology may uncover a full range of related targets, accounting for the whole spectrum of therapeutic activities of a drug (so-called “on-targets”) and/or explain unexpected side effects exerted through unsuspected targets (so-called “off-targets”).  Some drugs are active in whole cellular or animal models, but their active mechanisms remain unknown:  the YChemH technology may find a relevant target for these “orphan” drugs, in a process called “drug de-orphanisation”.  It may also be relevant for widely used chemicals in every day products to ascertain that they do not interact with any protein.

This new service offering covers a whole new area of involvement for Charnwood in protein interaction screening: with small molecules, making it unique. The venture has been conceived and developed to answer the unmet needs of the pharmaceutical industry and highlights our expertise in chemistry.  This, alongside the biological expertise held at Hybrigenics, means that we are involved in developments at the cutting edge of the biotech/chemical sector” said Sylvain Blanc, Business Development Manager of Charnwood Molecular. 

The venture comes at a key time for Charnwood Molecular as the company expands, having recently acquired a new laboratory site within BioCity, Nottingham, UK.